Editor`s Picks

Markets gained yesterday, but it was hardly convincing. The Russell 2000 is the best example as it posted its fourth day of doji/spinning top candlesticks - which post a net gain - but do so from...

The bull case for TWLO stock seems easy to make at a four-year low But the business is facing real challenges — and management isn’t responding Longer-term, this can still work, but...

Drugmaker Merck's (NYSE:MRK) stock has outperformed its competitors year to date (ytd), rising 30.6%. Pfizer (NYSE:PFE), which I am bearish on, is down 16.9% so far this year. The Rahway, New...

Stocks often surge in the months after mid-term elections Betting markets show high chance GOP snatches control of House and maybe even Senate Three investment themes that could catch tailwinds in...

Powell says Fed may slow pace of hikes but raise target Economists expect Fed to slow or halt quantitative tightening by mid-2023 Japan maintains low rates and supports yen as it hints at policy...

Technicals indicate a run toward $21 in first leg and $24 in second leg Weakness below $19.40 could trigger drop to $18.45 Silver an inflection point over potential to China’s COVID-Zero After...

November has been the best month of the year for U.S. stocks counting since 1950 AII investor sentiment has improved—although it remains below the historical average However, 2022 keeps adding...

Pfizer (NYSE:PFE) faces a $16 to $18 billion loss in revenue from 2025 through 2030 as it loses essential patents on five drugs.The drugs account for 40% of the company's Q3 revenue when its COVID...